Showing 1 - 11 results of 11 for search 'Derek T. Logan', query time: 0.04s Refine Results
  1. 1
    The Origin and Evolution of Ribonucleotide Reduction

    The Origin and Evolution of Ribonucleotide Reduction by Daniel Lundin, Gustav Berggren, Derek T. Logan, Britt-Marie Sjöberg

    Published 2015-02-01
    Get full text
    Article
  2. 2
    Solution Structure of the dATP-Inactivated Class I Ribonucleotide Reductase From Leeuwenhoekiella blandensis by SAXS and Cryo-Electron Microscopy

    Solution Structure of the dATP-Inactivated Class I Ribonucleotide Reductase From Leeuwenhoekiella blandensis by SAXS and Cryo-Electron Microscopy by Mahmudul Hasan, Ipsita Banerjee, Inna Rozman Grinberg, Britt-Marie Sjöberg, Derek T. Logan

    Published 2021-07-01
    Get full text
    Article
  3. 3
    Ser649 and Ser650 are the major determinants of protein kinase A-mediated activation of human hormone-sensitive lipase against lipid substrates.

    Ser649 and Ser650 are the major determinants of protein kinase A-mediated activation of human hormone-sensitive lipase against lipid substrates. by Christian Krintel, Peter Osmark, Martin R Larsen, Svante Resjö, Derek T Logan, Cecilia Holm

    Published 2008-01-01
    Get full text
    Article
  4. 4
    A nucleotide-sensing oligomerization mechanism that controls NrdR-dependent transcription of ribonucleotide reductases

    A nucleotide-sensing oligomerization mechanism that controls NrdR-dependent transcription of ribonucleotide reductases by Inna Rozman Grinberg, Markel Martínez-Carranza, Ornella Bimai, Ghada Nouaïria, Saher Shahid, Daniel Lundin, Derek T. Logan, Britt-Marie Sjöberg, Pål Stenmark

    Published 2022-05-01
    Get full text
    Article
  5. 5
    The Crystal Structure of Thermotoga maritima Class III Ribonucleotide Reductase Lacks a Radical Cysteine Pre-Positioned in the Active Site.

    The Crystal Structure of Thermotoga maritima Class III Ribonucleotide Reductase Lacks a Radical Cysteine Pre-Positioned in the Active Site. by Oskar Aurelius, Renzo Johansson, Viktoria Bågenholm, Daniel Lundin, Fredrik Tholander, Alexander Balhuizen, Tobias Beck, Margareta Sahlin, Britt-Marie Sjöberg, Etienne Mulliez, Derek T Logan

    Published 2015-01-01
    Get full text
    Article
  6. 6
    DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously

    DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously by Roland Beckmann, Kristian Jensen, Sebastian Fenn, Janina Speck, Katrin Krause, Anastasia Meier, Melanie Röth, Sascha Fauser, Raymond Kimbung, Derek T. Logan, Martin Steegmaier, Hubert Kettenberger

    Published 2021-01-01
    Get full text
    Article
  7. 7
    Novel ATP-cone-driven allosteric regulation of ribonucleotide reductase via the radical-generating subunit

    Novel ATP-cone-driven allosteric regulation of ribonucleotide reductase via the radical-generating subunit by Inna Rozman Grinberg, Daniel Lundin, Mahmudul Hasan, Mikael Crona, Venkateswara Rao Jonna, Christoph Loderer, Margareta Sahlin, Natalia Markova, Ilya Borovok, Gustav Berggren, Anders Hofer, Derek T Logan, Britt-Marie Sjöberg

    Published 2018-02-01
    Get full text
    Article
  8. 8
    Entropy–Entropy Compensation between the Protein, Ligand, and Solvent Degrees of Freedom Fine-Tunes Affinity in Ligand Binding to Galectin-3C

    Entropy–Entropy Compensation between the Protein, Ligand, and Solvent Degrees of Freedom Fine-Tunes Affinity in Ligand Binding to Galectin-3C by Johan Wallerstein, Vilhelm Ekberg, Majda Misini Ignjatović, Rohit Kumar, Octav Caldararu, Kristoffer Peterson, Sven Wernersson, Ulrika Brath, Hakon Leffler, Esko Oksanen, Derek T. Logan, Ulf J. Nilsson, Ulf Ryde, Mikael Akke

    Published 2021-04-01
    Get full text
    Article
  9. 9
    Interplay of halogen bonding and solvation in protein–ligand binding

    Interplay of halogen bonding and solvation in protein–ligand binding by Maria Luisa Verteramo, Majda Misini Ignjatović, Rohit Kumar, Sven Wernersson, Vilhelm Ekberg, Johan Wallerstein, Göran Carlström, Veronika Chadimová, Hakon Leffler, Fredrik Zetterberg, Derek T. Logan, Ulf Ryde, Mikael Akke, Ulf J. Nilsson

    Published 2024-04-01
    Get full text
    Article
  10. 10
    Structures of activin ligand traps using natural sets of type I and type II TGFβ receptors

    Structures of activin ligand traps using natural sets of type I and type II TGFβ receptors by Erich J. Goebel, Chandramohan Kattamuri, Gregory R. Gipson, Lavanya Krishnan, Moises Chavez, Magdalena Czepnik, Michelle C. Maguire, Rosa Grenha, Maria Håkansson, Derek T. Logan, Asya V. Grinberg, Dianne Sako, Roselyne Castonguay, Ravindra Kumar, Thomas B. Thompson

    Published 2022-01-01
    Get full text
    Article
  11. 11
    The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

    The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity by Mark F. Maurer, Katherine E. Lewis, Joseph L. Kuijper, Dan Ardourel, Chelsea J. Gudgeon, Siddarth Chandrasekaran, Sherri L. Mudri, Kayla N. Kleist, Chris Navas, Martin F. Wolfson, Mark W. Rixon, Ryan Swanson, Stacey R. Dillon, Steven D. Levin, Yengo Raymond Kimbung, Masato Akutsu, Derek T. Logan, Björn Walse, Kristine M. Swiderek, Stanford L. Peng

    Published 2022-04-01
    Get full text
    Article

Search Tools: